Numinus' Vancouver clinic will be used for collaboration on a clinical trial with MAPS for MDMA-assisted therapy for PTSD.
With ATAI eying a Spring 2021 IPO, it announces a $125 million private equity financing for Series C.
Novamind has closed on double its original target (CAD$5 million). Preparing to commence trading on the CSE (symbol "NM").
Revive Therapeutics and PharmaTher are teaming up to research the potential of psilocybin as a cancer treatment.
Field Trip announces a new clinics-based research program, beginning with psychedelic therapies for military veterans.